Japan Tissue Engineering Co (TSE:7774) LT-Debt-to-Total-Asset : 0.00 (As of Sep. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Japan Tissue Engineering Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Japan Tissue Engineering Co's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.00.

Japan Tissue Engineering Co's long-term debt to total assets ratio stayed the same from Jun. 2023 (0.00) to Sep. 2024 (0.00).

Japan Tissue Engineering Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for Japan Tissue Engineering Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Japan Tissue Engineering Co LT-Debt-to-Total-Asset Chart

Japan Tissue Engineering Co Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

Japan Tissue Engineering Co Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Sep24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Japan Tissue Engineering Co LT-Debt-to-Total-Asset Calculation

Japan Tissue Engineering Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (A: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Mar. 2024 )	/	Total Assets (A: Mar. 2024 )
	=	0	/	6988.774
	=	0.00

Japan Tissue Engineering Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )	/	Total Assets (Q: Sep. 2024 )
	=	0	/	6487.21
	=

Japan Tissue Engineering Co (TSE:7774) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Japan Tissue Engineering Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Japan Tissue Engineering Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Japan Tissue Engineering Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Japan Tissue Engineering Co Ltd (TSE:7774) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

6-209-1 Miyakitadori, Gamagori, Aichi, JPN, 443-0022

Website

https://www.jpte.co.jp

Japan Tissue Engineering Co Ltd is a bio-venture enterprise. It is engaged in the development, manufacture, and sale of tissue-engineered medical products and related products. It operates through the Regenerative Medicine, and Research and Development support business segments. The main business goal is to use autologous culturing techniques to develop tissue-engineered medical products and then to manufacture and sell these same tissue-engineered products to medical institutions for medical treatment. The company's tissue-engineered medical products are used in autologous transplant cases, where living cells are taken from the actual patient himself, cultured and then transplanted back to that same patient.

Japan Tissue Engineering Co Headlines

No Headlines